The peptide problem: Hype is outrunning the evidence The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Puts BPC 157, TB 500, and 5 Other Peptides Under the Microscope: What Prescribers Need to Know About the 503A Review Lengea FDA Peptide Update: Category 2 Removals Explained FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling